Alexza Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXA)   Watch this stock  
Find more results for ALXA
-0.007 (-0.78%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.94 - 0.98
52 week 0.22 - 1.60
Open 0.95
Vol / Avg. 32,308.00/181,562.00
Mkt cap 20.57M
P/E     -
Div/yield     -
EPS -1.22
Shares 21.75M
Beta 0.68
Inst. own 26%
Aug 4, 2016
Q2 2016 Alexza Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 11, 2016
Q1 2016 Alexza Pharmaceuticals Inc Earnings Call
May 11, 2016
Q1 2016 Alexza Pharmaceuticals Inc Earnings Release
Mar 28, 2016
Q4 2015 Alexza Pharmaceuticals Inc Earnings Call
Mar 28, 2016
Q4 2015 Alexza Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -466.94% -424.00%
Operating margin -222.78% -796.34%
EBITD margin - -736.63%
Return on average assets -106.54% -55.87%
Return on average equity - -
Employees 27 -
CDP Score - -


2091 Stierlin Ct
MOUNTAIN VIEW, CA 94043-4655
United States - Map
+1-650-9447000 (Phone)
+1-650-9447999 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research development and commercialization of products for the acute treatment of central nervous system (CNS) conditions. The Company's product candidates are based on its technology the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled allows for systemic drug delivery. It has two product candidates in active development, AZ-002 and AZ-007. Its product AZ-002 contains Staccato alprazolam as an active ingredient. AZ-002 is indicated for the treatment of Acute Repetitive Seizures. It initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy. Its product AZ-007 contains Staccato zaleplon as an active ingredient. It is developing AZ-007 for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening who have difficulty falling back asleep.

Officers and directors

Tom B. King President, Chief Executive Officer, Principal Financial Officer & Principal Accounting Officer, Director
Age: 60
Bio & Compensation  - Reuters
Edwin S. Kamemoto Ph.D. Executive Vice President - R&D and Quality
Age: 61
Bio & Compensation  - Reuters
Lori H, Takahashi PhD Vice President - Pharmaceutical R&D & Quality
Bio & Compensation  - Reuters
Isaac Stein Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
J. Kevin Buchi Independent Director
Age: 59
Bio & Compensation  - Reuters
Deepika R. Pakianathan Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
J. Leighton Read M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Gordon Ringold Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters